Analysis shows Yeztugo approval a ‘momentous step’ for HIV prevention
Pharmaceutical Technology
JULY 2, 2025
Gilead’s recently approved drug for HIV prevention, Yeztugo (lenacapavir), has the potential to transform the pre-exposure prophylaxis (PrEP) sector in the US, according to market analysts. Go deeper with GlobalData Reports LOA and PTSR Model - BRII-732 in Human Immunodeficiency Virus (HIV).
Let's personalize your content